In the BioHarmony Drug Report Database
Imlifidase
Idefirix (imlifidase) is an enzyme pharmaceutical. Imlifidase was first approved as Idefirix on 2020-08-25. It has been approved in Europe to treat immunologic desensitization and kidney transplantation.
Trade Name
|
Idefirix |
|---|---|
Common Name
|
imlifidase |
ChEMBL ID
|
CHEMBL4297981 |
Indication
|
immunologic desensitization, kidney transplantation |
Drug Class
|
Enzymes |
Image (chem structure or protein)
